The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

Jihad Georges Youssef; Philip Lavin; David A. Schoenfeld; Richard A. Lee; Rainer Lenhardt; David J. Park; Javier Perez Fernandez; Melvin L. Morganroth; Jonathan C. Javitt; Dushyantha Jayaweera

doi:10.1097/CCM.0000000000005660

Back

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

Journal article

Open access

Peer reviewed

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

Jihad Georges Youssef, Philip Lavin, David A. Schoenfeld, Richard A. Lee, Rainer Lenhardt, David J. Park, Javier Perez Fernandez, Melvin L. Morganroth, Jonathan C. Javitt and Dushyantha Jayaweera

Critical care medicine, Vol.50(11), pp.1545-1554

2022-10-13

DOI: https://doi.org/10.1097/CCM.0000000000005660

PMID: 36044317

Appears in Miller School of Medicine - Latest Publications

Abstract

acute lung injury

acute respiratory distress syndrome

alveolar type II

coronavirus

COVID-19

severe acute respiratory syndrome coronavirus 2

surfactant

vasoactive intestinal peptide

Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.

Files and links (1)

url

https://journals.lww.com/ccmjournal/Fulltext/9900/The_Use_of_IV_Vasoactive_Intestinal_Peptide.40.aspxView

Published (Version of record) Open

Metrics

10 Record Views

2 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.195 Neuroendocrine & Intestinal Disorders; 1.195.578 Adrenomedullin
Web Of Science research areas: Critical Care Medicine
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
Creators: Jihad Georges Youssef - Houston Methodist
Philip Lavin - Boston Biostatistics Research Foundation Inc, Framingham, MA.
David A. Schoenfeld - Massachusetts General Hospital
Richard A. Lee - University of California, Irvine
Rainer Lenhardt - University of Louisville
David J. Park - St. Jude Medical Center
Javier Perez Fernandez - Baptist Memorial Hospital
Melvin L. Morganroth - Oregon Clinic
Jonathan C. Javitt - Johns Hopkins Medicine
Dushyantha Jayaweera - University of Miami
Publication Details: Critical care medicine, Vol.50(11), pp.1545-1554
Publisher: Lippincott Williams & Wilkins
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Infectious Diseases
Language: English
Resource Type: Journal article
PMID: 36044317
Record Identifier: 991031757793402976